ecancermedicalscience

Case Report

Pegylated Liposomal Doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo

9 Dec 2008
Y Yuan, SJ Orlow, J Curtin, A Downey, F Muggia

Pegylated liposomal doxorubicin (PLD, Doxil, Caelyx) is widely used for the treatment of ovarian cancer. It is a stable formulation encapsulating doxorubicin in a ‘Stealth’ (i.e., pegylated) liposome with a half-life of about 72 hours. This drastically altered pharmacology confers on it a considerably lower risk of cardiotoxicity, no acute emesis, and near absence of alopecia or problems with extravasation necrosis. On the other hand, PLD's dose-limiting toxicity is cutaneous. Since the original phase I report, cutaneous toxicities reported with PLD fall into four common categories: the well known hand-foot syndrome (also called palmoplantar erythrodysesthesia, or PPE), a diffuse follicular rash, intertrigo-like eruption, and hyperpigmentation including melanotic macules.

Artículos relacionados

José Fernando Robles Díaz, Adela Heredia Zelaya, Alicia Milagros Avalos Rosas
María Eugenia Giavedoni, Lucas Staringer, Rosa Garrido, Cintia Bertoncini, Mabel Sardi, Myriam Perrotta
Daniela Speisky, María Teresa García de Davila, Felix Vigovich, Julian Mendez, Rafael Maurette, Marcos García Ejarque, Juan Carlos Spina, Alejandro Iotti, Pablo Dezanzo